Lipids & Statins · Note 20
Discontinuing Statins in Older Adults without Cardiovascular Disease
A New England Journal of Medicine trial examined what happens when older adults without cardiovascular disease discontinue statin therapy.
Clinical guidelines generally support statins for older adults at elevated risk, but the evidence base in people over 70 is thinner than in middle age. Many older patients take a statin for primary prevention and wonder whether the pill still earns its place in an already long medication list.
The NEJM trial addresses that question directly by randomly assigning older adults without cardiovascular disease to stop or continue treatment. Randomisation is important here because people who stop medicines are often different from those who persist, and observational comparisons can mislead in either direction.
This note is based on the published trial record rather than the full results discussion, so the specific event rates and the duration of follow-up should be read at the source. What the trial can do is inform a conversation about prevention in later life; it cannot decide for an individual patient with a particular set of risks and preferences.
Keep in mind
- Evidence for primary prevention in this age group has been limited.
- The decision remains individual and should be discussed with a clinician.
Source and reuse
This is an independent editorial summary written for Heartline. It is not a verbatim reproduction and does not reproduce paywalled text. Reporting, data and quotations belong to NEJM. Read the original at the link provided.
Metadata basis: the publisher’s public RSS feed and the abstract it exposes. Where the full article could not be accessed, this note is explicitly metadata-based and limited to what the feed disclosed. It is not medical advice.
Read the original at NEJM →